Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: After administering medication, patient symptoms in groups B, C and D were relieved - most significantly in group D (P<0.05). There were no significant differences in endoscopic hyperemia and histological inflammation among the groups (P>0.05). However, histological activity, the number of reflux episodes and the number of reflux episodes lasting longer than 5 min were significantly decreased only in group D (P<0.05). The total per cent of bilirubin absorption (value of 0.14 units or greater) time was decreased in groups B, C and D, and most significantly in group D (P<0.05). CONCLUSION:
|
Authors | Huimin Chen, Xiaobo Li, Zhizheng Ge, Yunjie Gao, Xiaoyu Chen, Yun Cui |
Journal | Canadian journal of gastroenterology = Journal canadien de gastroenterologie
(Can J Gastroenterol)
Vol. 24
Issue 3
Pg. 197-201
(Mar 2010)
ISSN: 0835-7900 [Print] Canada |
PMID | 20352149
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Antacids
- Anti-Ulcer Agents
- hydrotalcite
- Rabeprazole
- Aluminum Hydroxide
- Magnesium Hydroxide
- Bilirubin
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
(administration & dosage, therapeutic use)
- Adult
- Aged
- Aluminum Hydroxide
(administration & dosage, therapeutic use)
- Antacids
(administration & dosage, therapeutic use)
- Anti-Ulcer Agents
(administration & dosage, therapeutic use)
- Bile Reflux
(drug therapy, etiology)
- Bilirubin
(metabolism)
- Cholecystectomy
(adverse effects)
- Drug Therapy, Combination
- Female
- Gastritis
(drug therapy, etiology)
- Gastroscopy
- Humans
- Magnesium Hydroxide
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Rabeprazole
- Time Factors
|